Ezetimibe/rosuvastatin
Combination drug for hyperlipidemia
Ezetimibe/rosuvastatin is a combination drug used to treat hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. This medication combines two active ingredients: ezetimibe and rosuvastatin.
Mechanism of Action[edit | edit source]
Ezetimibe/rosuvastatin works by targeting different pathways involved in cholesterol metabolism.
Ezetimibe[edit | edit source]
Ezetimibe is a cholesterol absorption inhibitor. It acts on the small intestine to block the absorption of cholesterol from the diet. By inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein, ezetimibe reduces the amount of cholesterol delivered to the liver, leading to a decrease in blood cholesterol levels.
Rosuvastatin[edit | edit source]
Rosuvastatin is a member of the statin class of drugs, which are HMG-CoA reductase inhibitors. Statins work by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the synthesis of cholesterol in the liver. This results in an upregulation of LDL receptors on liver cells, increasing the clearance of low-density lipoprotein (LDL) cholesterol from the bloodstream.
Clinical Use[edit | edit source]
Ezetimibe/rosuvastatin is primarily prescribed for patients with hypercholesterolemia who require additional lipid-lowering effects beyond what can be achieved with statin therapy alone. It is particularly useful in patients who have not reached their target cholesterol levels with statins alone or who have familial hypercholesterolemia.
Dosage and Administration[edit | edit source]
The dosage of ezetimibe/rosuvastatin is individualized based on the patient's current cholesterol levels, response to treatment, and risk factors for cardiovascular disease. It is typically administered once daily, with or without food.
Side Effects[edit | edit source]
Common side effects of ezetimibe/rosuvastatin include muscle pain, headache, and gastrointestinal disturbances. Serious side effects, although rare, can include rhabdomyolysis, liver enzyme abnormalities, and allergic reactions.
Contraindications[edit | edit source]
Ezetimibe/rosuvastatin is contraindicated in patients with active liver disease, unexplained persistent elevations of serum transaminases, and in women who are pregnant or breastfeeding.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD